BMS-986165
- CAS No.
- 1609392-27-9
- Chemical Name:
- BMS-986165
- Synonyms
- Deucravacitinib;6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl) phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide;Tyk2-IN-4;Deucravacitinb;BMS-986165 API;Deucravacitinib (TYK2-IN-4;Deucravacitinib(BMS986165);TYK2-IN-4;BMS986165;BMS-986165;BMS 986165;DeucravacitinibQ: What is Deucravacitinib Q: What is the CAS Number of Deucravacitinib;6-cyclopropaneamido-4-{[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino}-N-(2H?)methylpyridazine-3-carboxamide
- CBNumber:
- CB74808663
- Molecular Formula:
- C20H22N8O3
- Molecular Weight:
- 422.45
- MDL Number:
- MOL File:
- 1609392-27-9.mol
storage temp. | Store at -20°C |
---|---|
solubility | DMF: 1 mg/ml; DMSO: 1 mg/ml; DMSO:PBS (pH 7.2) (1:2): 0.33 mg/ml |
form | A crystalline solid |
color | Off-white to light yellow |
FDA UNII | N0A21N6RAU |
SAFETY
Risk and Safety Statements
Symbol(GHS) | GHS08 |
---|---|
Signal word | Danger |
Hazard statements | H361f-H372 |
Precautionary statements | P260-P264-P270-P314-P501 |
BMS-986165 price
Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|---|
ChemScene | CS-0065044 | BMS-986165 99.79% | 1609392-27-9 | 10mg | $350 | 2021-12-16 | Buy |
ChemScene | CS-0065044 | BMS-986165 99.79% | 1609392-27-9 | 50mg | $850 | 2021-12-16 | Buy |
DC Chemicals | DC12174 | Deucravacitinib(BMS986165) >98% | 1609392-27-9 | 250mg | $1100 | 2021-12-16 | Buy |
DC Chemicals | DC12174 | Deucravacitinib(BMS986165) >98% | 1609392-27-9 | 1g | $2200 | 2021-12-16 | Buy |
Crysdot | CD31005021 | 6-[(Cyclopropylcarbonyl)amino]-4-{[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino}-N-(2H3)methyl-3-pyridazinecarboxamide 98% | 1609392-27-9 | 5mg | $450 | 2021-12-16 | Buy |
BMS-986165 Chemical Properties,Uses,Production
Uses
BMS-986165 is a novel oral selective TYK2 inhibitor with a unique mechanism of action that is expected to provide a promising oral option to help patients effectively manage their psoriasis.
Uses
Deucravacitinib is a tyrosine kinase 2 inhibitor which can be useful in the treatment of systemic lupus erythematosus.
General Description
Deucravacitinib, a highly selective allosteric TYK2 inhibitor, received its first approval from the FDA in 2022 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy protein and lipid kinases and pseudokinases with the exception of BMPR2 (IC50 = 193 nM) and JAK1 JH2 pseudokinase domain (IC50 = 1 nM). Despite its potent affinity for JAK1 JH2, deucravacitinib elicited low functional activity in a JAK1/JAK3-dependent IL-2 stimulated cellular assay. BMS-986202 displays >10,000-fold selectivity for TYK2 JH2 over a diverse panel of 273 kinases and pseudokinases that include JAK family members. Like deucravacitinib, its high binding affinity to JAK1 JH2 (IC50 = 7.8 nM) did not translate to functional activity in the cellular assay.
Pharmacokinetics
The crystalline free base form of deucravacitinib exhibited poor aqueous solubility (5.2 μg/mL), which was still acceptable for preclinical studies. It showed moderate half-lives of 4?5 h across species (mouse, dog, and monkey). Excellent exposures and high bioavailability (F > 85%) in mice, dogs, and monkeys were obtained from oral pharmacokinetic studies at a 10 mpk dose. Following oral administration of deucravacitinib, the major metabolite in human plasma was the cyclopropyl carboxamide hydrolytic cleavage product 4 (6-amino-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-methylpyridazine-3-carboxamide).
BMS-986165 Preparation Products And Raw materials
Raw materials
1of3
Preparation Products
BMS-986165 Suppliers
Supplier | Tel | Country | ProdList | Advantage | |
---|---|---|---|---|---|
Zhengzhou Anbu Chem Co.,Ltd | +86-0371-88006763; +8615988602810 | sales@anbuchem.com | China | 3000 | 58 |
Hangzhou ICH Biofarm Co., Ltd | +86-0571-28186870; +undefined8613073685410 | sales@ichemie.com | China | 990 | 58 |
hebei hongtan Biotechnology Co., Ltd | +86-86-1913198-3935 +8617331935328 | sales03@chemcn.cn | China | 973 | 58 |
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. | +86-18600796368 +86-18600796368 | sales@sjar-tech.com | China | 251 | 58 |
Jinan Jianfeng Chemical Co., Ltd | +8615562555968 | info@pharmachemm.com | China | 247 | 58 |
BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19553 | 58 |
TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 | marketing@targetmol.com | United States | 19892 | 58 |
Dideu Industries Group Limited | +86-29-89586680 +86-15129568250 | 1026@dideu.com | China | 24099 | 58 |
Zhejiang J&C Biological Technology Co.,Limited | +1-2135480471 +1-2135480471 | sales@sarms4muscle.com | China | 10522 | 58 |
Hangzhou Proserre Chemical Co.,Ltd. | +86-571-86088112 | info@proserre.com | China | 1077 | 58 |
View Lastest Price from BMS-986165 manufacturers
Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
---|---|---|---|---|---|---|---|---|
2024-09-19 | BMS-986165 API
1609392-27-9
|
US $100.00-80.00 / KG | 1KG | 99.9% | 500 | hebei hongtan Biotechnology Co., Ltd | ||
2024-09-19 | Deucravacitinib
1609392-27-9
|
US $20.00 / g | 100g | 99.9% | 1000kg | hebei hongtan Biotechnology Co., Ltd | ||
2024-09-18 | BMS-986165
1609392-27-9
|
US $0.00 / KG | 1KG | 99% min | 20 TONS | Wuhan Senwayer Century Chemical Co.,Ltd |
- BMS-986165 API
1609392-27-9
- US $100.00-80.00 / KG
- 99.9%
- hebei hongtan Biotechnology Co., Ltd
- Deucravacitinib
1609392-27-9
- US $20.00 / g
- 99.9%
- hebei hongtan Biotechnology Co., Ltd
- BMS-986165
1609392-27-9
- US $0.00 / KG
- 99% min
- Wuhan Senwayer Century Chemical Co.,Ltd